We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".
- Authors
Padula, William V.; Parasrampuria, Sonal; Socal, Mariana P.; Conti, Rena M.; Anderson, Gerard F.
- Abstract
Extended monopoly periods enable drug manufacturers to increase drug prices without facing competition from generics or biosimilars, which ultimately may have serious effects in compromising affordability and patient access. Provided the reference drug has unexpired market exclusivity for a given condition, the insurer has an incentive to cover the reference drug (to avoid the potential liability of off-label prescribing). Drug manufacturers tend to offer price concessions according to the drug's market share and may choose to withdraw or reduce price concessions if the reference product loses market share to the competitor.
- Subjects
ORPHAN drugs; DRUG marketing; BOTULINUM A toxins; RESEARCH; RESEARCH methodology; EVALUATION research; COMPARATIVE studies; DRUGS; SYMPTOMS; IMPACT of Event Scale; RESEARCH funding; BUDGET
- Publication
PharmacoEconomics, 2020, Vol 38, Issue 12, p1375
- ISSN
1170-7690
- Publication type
letter
- DOI
10.1007/s40273-020-00973-9